Cost-effectiveness and cost-utility of long-term management strategies for heartburn

Value in Health

Volumn 5, Issue 4, 2002, Pages 312-328

  Goeree, Ron ^a,b,c   O'Brien, Bernie J ^a,b   Blackhouse, Gordon ^a,b   Marshall, John ^b   Briggs, Andrew ^c   Lad, Rameeta ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cost effectiveness analysis; Cost utility analysis; Economic evaluation; Heartburn

Indexed keywords

CIMETIDINE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE;

ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECISION MAKING; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG COST; HEALTH SURVEY; HEARTBURN; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; META ANALYSIS; MONTE CARLO METHOD; OUTCOMES RESEARCH; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RECURRENCE RISK; SENSITIVITY ANALYSIS; SIMULATION; SYMPTOMATOLOGY;

EID: 0043026642     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.2002.54145.x     Document Type: Article

References (77)

1. Tougas G, Chen Y, Hwang P, et al. Prevalence and impact of upper gastrointestinal symptoms in the Canadian population: findings from the DIGEST study. Am J Gastroenterol 1999;94:2845-54.
2. Levin TR, Schmittdiel JA, Kunz K, Henning JM, et al. Costs of acid-related disorders to a health maintenance organization. Am J Med 1997;103:520-8.
3. Henke CJ, Levin TR, Henning JM, Potter LP. Work loss costs due to peptic ulcer disease and gastroesophageal reflux disease in a health maintenance organization. Am J Gastroenterol 2000;95:788-92.
4. Russo MW, Gaynes BN, Drossman DA. A national survey of practice patterns of gastroenterologists with comparison to the past two decades. J Clin Gastroenterol 1999;29:339-43.
5. Hungin AP, Rubin GP, O'Flanagan H. Long-term prescribing of proton pump inhibitors in general practice. Brit J Gen Pract 1999;49:451-3.
6. Graham DY, Smith JL, Patterson DJ. Why do apparently healthy people use antacid tablets? Am J Gastroenterol 1983;78:257-60.
7. Chiba N, Wilkinson J, Hunt RH. Symptom relief in erosive GERD: a meta-analysis. Am J Gastroenterol 1993;88:A1486.
8. Chiba N, deGara CJ, Burget D, et al. Rapidity of healing in GERD: a comparison of different drug classes by meta-analysis. Gastroenterology 1993;104:A53.
9. Goeree R, O'Brien B, Hunt R, et al. Economic evaluation of long-term management strategies for erosive oesophagitis. Pharmacoeconomics 1999;16:679-97.
10. Harris RA, Kuppermann M, Richter JE. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis. Am J Gastroenterol 1997;92:2179-87.
11. Klauser AG, Schindlbeck NE, Muller-Lissner SA. Symptoms in gastro-esophageal reflux disease. Lancet 1990;335:205-8.
12. Jones RH, Hungin PS, Phillips J, Mills JG. Gastroesophageal reflux disease disease in primary care in Europe: clinical presentation and endoscopic findings. Eur J Gen Pract 1995;1:149-54.
13. Veldhuyzen van Zanten SJ, Flook N, Chiva N, et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori: the Canadian Dyspepsia Working Group. CMAJ 2000;162:S3-23.
14. Chiba N, deGara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in Grade II to IV gastroesophegial reflux disease: a meta-analysis. Gastroenterology 1997;112:1798-810.
15. Heudebert GR, Centor RM, Klapow JC, et al. What is heartburn worth: a cost-utility analysis of management strategies. J Gent Int Med 2000;15:175-82.
16. Gerson L, Robbins A, Garber A, Hornberger JTG. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am J Gastroenterol 2000;95:397-407.
17. Ontario Ministry of Health. Schedule of Benefits: Physician services under the Health Insurance Act. Ontario Ministry of Health, 1992.
18. Ontario Hospital Association. Ontario Case Costing Project: Ontario guide to case costing. Toronto: Ontario Hospital Association, 1995.
19. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
20. Pratt JW, Raiffa H, Schlaifer R. Introduction to Statistical Decision Theory. 2nd printing, 1996 ed. Cambridge, MA: MIT Press, 1995.
21. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998;18:S65-80.
22. Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998;279:1445-51.
23. Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res 1993;2:121-45.
24. Witt DM, Lousberg TR. Controversies surrounding estrogen use in postmenopausal women. Ann Pharmacother 1997;31:745-55.
25. Laupacis A, Feeny D, Detsky A, Tugwell P. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1993;148:913-7.
26. Bate CM, Green JRB, Axon ATR, et al. Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis. Aliment Phamacol Ther 1997;11:755-63.
27. Dehn TCB, Shepherd HA, Colin-Jones D, et al. Double-blind comparison of omeprazole (40 mg od) versus cimetidine (400 mg qd) in the treatment of symptomatic erosive reflux oesophagitis assessed endoscopically, histologically and by 24 h pH monitoring. Gut 1990;31:509-13.
28. Bate CM, Keeling PW, O'Morain C, et al. Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic, and histological evaluations. Gut 1990;31:968-72.
29. Hameeteman W, v d Boomgard DM, Dekker W, Schrijver M, et al. Sucralfate versus cimetidine in reflux esophagitis. A single-blind multicenter study. J Clin Gastroenterol 1987;9:390-4.
30. Wesdorp E, Bartelsman J, Pape K, et al. Oral cimetidine in reflux esophagitis: A double blind controlled trial. Gastroenterology 1978;74:821-4.
31. Bright-Asare P, El-Bassoussi M. Cimetidine, metoclopramide, or placebo in the treatment of symptomatic gastroesophageal reflux. J Clin Gastroenterol 1980;2:149-56.
32. Tytgat GN. Clinical efficacy of sucralfate in reflux esophagitis. Comparison with cimetidine. Am J Med 1987;83(3B):38-42.
33. Sabesin SM, Berlin RG, Humphries TJ, et al. Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USA Merck Gastroesophageal Reflux Disease Study Group [see comments]. Arch Intern Med 1991;151:2394-400.
34. Robinson M, Decktor DL, Stone RC, et al. Famotidine (20 mg) b.d. relieves gastrooesophageal reflux symptoms in patients without erosive oesophagitis. Famotidine/GERD Investigation Group. Aliment Pharmacol Ther 1991;5:631-43.
35. Hungin APS, Gunn SD, Bate CM, et al. A comparison of the efficacy of omeprazole 20 mg once daily with ranitidine 150 mg bid in the relief of symptomatic gastro-oesophageal reflux disease in general practice. Brit J Clin Res 1993;4:73-88.
36. Bate CM, Crowe JP, Dickinson RJ. Reflux oesophagitis resolves more rapidly with omeprazole 20 mg once daily than with ranitidine 150 mg bd: omeprazole 40 mg once daily provides further benefit in unresponsive patients. Brit J Clin Res 1991;2:133-48.
37. Londong W, Phillips J, Johnson NJ, Wood JR. The effect of combined therapy with ranitidine and pirenzepine in the treatment of reflux oesophagitis. Aliment Pharmacol Ther 1992;6:609-18.
38. Klinkenberg-Knol EC, Jansen JM, Festen HP, et al. Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet 1987;1:349-51.
39. Vantrappen G, Rutgeerts L, Schurmans P, Coenegrachts JL. Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis. Dig Dis Sci 1988;33:523-9.
40. Koop H, Schepp W, Dammann HG, et al. Comparative trial of pantoprazole and ranitidine in the treatment of reflux esophagitis. Results of a German multicenter study. J Clin Gastroenterol 1995;20:192-5.
41. Johnson NJ, Boyd EJ, Mills JG, Wood JR. Acute treatment of reflux oesophagitis: a multicentre trial to compare 150 mg ranitidine b.d. with 300 mg ranitidine q.d.s. Aliment Pharmacol Ther 1989;3:259-66.
42. Bianchi Porro G, Pace F, Peracchia A, et al. Short-term treatment of refractory reflux esophagitis with different doses of omeprazole or ranitidine. J Clin Gastroenterol 1992;15:192-8.
43. Maton PN, Orlando R, Joelsson B. Efficacy of omeprazole versus ranitidine for symptomatic treatment of poorly responsive acid reflux disease - a prospective controlled trial. Aliment Phamacol Ther 1999;13:819-26.
44. Bardhan KD, Muller-Lissner S, Bigard MA, et al. Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. BMJ 1999;318:502-7.
45. Kahrilas PJ, Fennerty MB, Joelsson B. High-versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease: A prospective, controlled trial. Am J Gastroenterol 1999;94:92-7.
46. Bardhan KD, Hawkey CJ, Long RG, et al. Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group. Aliment Phamacol Ther 1995;9:145-51.
47. Dakkak M, Jones BP, Scott MG, et al. Comparing the efficacy of cisapride and ranitidine in oesophagitis: a double-blind, parallel group study in general practice. Br J Clin Pract 1994;48:10-4.
48. Havelund T, Laursen LS, Skoubo-Kristensen E, et al. Omeprazole and ranitidine in treatment of reflux oesophagitis: double blind comparative trial. Br Med J (Clin Res Ed) 1988;296:89-92.
49. Italian Reflux Oesophagitis Study Group. Omeprazole produces significantly greater healing of erosive or ulcerative reflux oesophagitis than ranitidine. The Italian reflux oesophagitis study group. Eur J Gastroenterol Hepatol 1991;3:511-7.
50. Richter JE, Sabesin SM, Kogut DG, et al. Omeprazole versus ranitidine or ranitidine/metoclopramide in poorly responsive symptomatic gastroesophageal reflux disease. Am J Gastroenterol 1996;91:1766-72.
51. Schaub N, Thomas JM, Misiewicz JJ et al. Investigation of ranitidine 150 mg bd or 300 mg bd in the treatment of reflux disease. Hepatogastroenterology 1986;33:208-13.
52. Venables T, Newland R, Patel AC, et al. A comparison of omeprazole 10 mg and 20 mg OM with ranitidine 150 mg BD for the treatment of GORD in primary care. Gut 1995;37(Suppl. 2):A45.
53. Bovero E, Cheli R, Barbara L, et al. Short-term treatment of reflux oesophagitis with ranitidine 300 mg nocte. Italian multicentre study. Hepatogastroenterology 1987;34:155-9.
54. Simon B, Mueller P. Comparison of the effect of sucralfate and ranitidine in reflux esophagitis. Am J Med 1987;83:43-7.
55. Johnson NJ, Laws S, Mills JG, Wood JR. Effect of three ranitidine dosage regimens in the treatment of reflux oesophagitis: results of a multicentre trial. Eur J Gastroenterol Hepatol 1991;3:769-74.
56. Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Phamacol Ther 1997;11:765-73.
57. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988;95:903-12.
58. Sontag SJ, Hirschowitz BI, Holt S, et al. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. Multicenter Study. Gastroenterology 1992;102:109-18.
59. Mossner J, Holscher AH, Herz R, Schneider A. A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. Aliment Pharmacol Ther 1995;9:321-6.
60. Bate CM, Booth SN, Crowe JP, et al. Does 40 mg omeprazole daily offer additional benefit over 20 mg daily in patients requiring more than 4 weeks of treatment for symptomatic reflux oesophagitis? [see comments]. Aliment Pharmacol Ther 1993;7:501-7.
61. Robinson M, Decktor DL, Maton PN, et al. Omeprazole is superior to ranitidine plus metoclopramide in the short-term treatment of erosive oesophagitis. Aliment Pharmacol Ther 1993;7:67-73.
62. Corinaldesi R, Valentini M, Belaiche J, et al. Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study. Aliment Pharmacol Ther 1995;9:667-71.
63. Hatlebakk JG, Hyggen A, Masden PH, et al. Heartburn treatment in primary care: randomised, double blind study for 8 weeks. BMJ 1999;319:550-3.
64. Dekkers CPM, Beker JA, Thjodleifsson B, et al. Double-blind, placebo-controlled comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. Aliment Phamacol Ther 1999;13:49-57.
65. Bate CM, Griffin SM, Keeling PW, et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther 1996;10:547-55.
66. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. Eur J Gastroenterol 1998;10:119-24.
67. Laursen LS, Bondesen S, Hansen J, et al. Omeprazole 20 mg or 40 mg daily for the treatment of gastroesophageal reflux disease? A double-blind comparative study. Gastroenterology 1992;102: A110.
68. Robinson M, Campbell DR, Sontag S, Sabesin SM. Treatment of erosive reflux esophagitis resistant to h2-receptor antagonist therapy. lansoprazole, a new proton pump inhibitor. Dig Dis Sci 1995;40:590-7.
69. Mulder CJ, Dekker W, Gerretsen M. Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II, III and IVa (a Dutch multicentre trial). Dutch Study Group. Eur J Gastroenterol Hepatol 1996;8:1101-6.
70. Lundell L, Backman L, Ekstrom P, et al. Omeprazole or high-dose ranitidine in the treatment of patients with reflux oesophagitis not responding to "standard doses" of H2- receptor antagonists. Aliment Pharmacol Ther 1990;4:145-55.
71. Bate CM, Booth SN, Crowe JP, et al. Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Solo investigator group. Gut 1995;36:492-8.
72. Hegarty JH, Halvorsen L, Hazenberg BP, et al. Prevention of relapse in reflux esophagitis: a placebo controlled study of ranitidine 150 mg bid and 300 mg bid. Can J Gastroenterol 1997;11:83-8.
73. Laursen LS, Havelund T, Bondesen S, et al. Omeprazole in the long-term treatment of gastro-oesophageal reflux disease. A double-blind randomized dose-finding study. Scand J Gastroenterol 1995;30:839-46.
74. Robinson M, Lanza F, Avner D, Haber M. Effective maintenance treatment of reflux esophagitis with low- dose lansoprazole. a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;124:859-67.
75. Sontag SJ, Kogut DG, Fleischmann R, et al. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The Lansoprazole Maintenance Study Group. Am J Gastroenterol 1996;91:1758-65.
76. Hallerback B, Unge P, Carling L, et al. Omeprazole or ranitidine in long-term treatment of reflux esophagitis. the scandinavian clinics for united research group [see comments]. Gastroenterology 1994;107:1305-11.
77. Gough AL, Long RG, Cooper BT, et al. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther 1996;10:529-39.